Starting Wednesday, the U.S. imposed 100% tariffs on imports of branded or patented pharmaceutical products that President Trump announced last week. This sweeping measure targets foreign-made drugs to push manufacturers toward U.S. production and bolster domestic supply chains.
The tariffs coincide with pricing pressures, but a landmark deal sets pharma apart. Tuesday, Pfizer (NYSE:PFE) reached a voluntary agreement with the government to align U.S. prices for new drugs with the lowest in developed nations, including most-favored-nation rates for Medicaid via a new TrumpRx.gov site.
The new tariff regime tilts the field toward U.S.-centric drugmakers, making these three clear buys for growth ahead.
This post originally appeared at 24/7 Wall St.